Overview

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

Status:
Active, not recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

CLL2-BAAG is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of debulking with bendamustine followed by induction and maintenance with GA101 (obinutuzumab), acalabrutinib (ACP-196) and venetoclax (ABT-199) in patients with relapsed/refractory CLL.

Phase:

Phase 2

Details

Lead Sponsor:

German CLL Study Group

Treatments:

Acalabrutinib
Bendamustine Hydrochloride
Obinutuzumab
Venetoclax